What this means
This trial plans to test whether early heart rehab can help older heart patients who also lose muscle. It has not started, so no results exist yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 60–90
- Where
- Not listed
The science
- Registered title
- The Therapeutic Effect of Phase I Cardiac Rehabilitation on Elderly Patients With CHD Complicated by Sarcopenia
- Trial ID
- NCT07197463 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Coronary Disease, Sarcopenia
- What is tested
- drug therapy （Aspirin, Atorvastatin, Nitroglycerin）+ general treatment（quit smoking）
- Sponsor
- Qilu Hospital of Shandong University
- Ages
- 60 Years to 90 Years
- Dates
- First posted Sep 29, 2025 · updated Sep 29, 2025
Registry summary
The purpose of this clinical trial is to explore whether Phase I cardiac rehabilitation can treat elderly patients with coronary heart disease complicated by sarcopenia. It will also investigate the mechanism of Phase I cardiac rehabilitation. The main questions it aims to answer are:
- Can Phase I cardiac rehabilitation enhance muscle strength ?
- Can Phase I cardiac rehabilitation reduce in vivo inflammatory indicators? Researchers will compare the experimental group (Phase I cardiac rehabilitation + drug therapy + general treatment) with the control group (drug therapy + general treatment) to see if Phase I cardiac rehabilitation can treat elderly patients with coronary heart disease complicated by sarcopenia and reduce inflammatory indicators.
Participants will:
- Receive Phase I cardiac rehabilitation training（mainly includes low-intensity resistance training, breathing training and bedside cycling） or conventional drug therapy for 3 consecutive months.
- Undergo examinations 10 days after training, 1 month after discharge, and 3 months after discharge respectively.
- Record changes in their muscle strength and blood inflammatory indicators.